Genzyme rare-disease drug gets priority label

Share this article:

The FDA granted priority review status to Genzyme's experimental, all-oral Gaucher's disease treatment Cerdelga (eliglustat).

The FDA's priority label means the regulator will decide for or against the twice-a-day pill within six months.

The Sanofi subsidiary said in a statement that the 400-patient clinical trial supporting the filing is the largest ever conducted for Gaucher's disease.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.